Advertisement

Topics

Companies Related to "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study" [Most Relevant Company Matches] RSS

02:29 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study" found in our extensive corporate database of over 50,000 company records.

Showing "Antigonadotropin Leuprolide Alzheimer Disease Drug INvestigation ALADDIN Study" Companies 1–25 of 6,000+

Extremely Relevant

Alzheimer's Drug Discovery Foundation (ADDF)

Alzheimer's Drug Discovery Foundation (http://www.alzdiscovery.org/) is the only public charity whose sole mission is to fund drug discovery and development to prevent, treat, and cure Alzheimer's disease and cognitive aging. An affiliated public charity of the Institute for the Study of Aging (ISOA), a private foundation established by the Estee Lauder family in 1998, ADDF was established in 2004...


Relevant

Institute for The Study of Aging

Venture philanthropy is an evolving term that has been used to describe a variety of charitable operating models. Biomedical Venture Philanthropy describes a new model that has evolved to foster drug discovery research and development. The Institute for the Study of Aging (ISOA) has adopted this model to fund drug discovery research and development for Alzheimer’s disease.Operating like a ventur...

Axonyx

Axonyx is a biopharmaceutical company focused on the acquisition and development of proprietary products and technologies for the treatment and diagnosis of Alzheimer's Disease and other memory-related cognitive disorders including prion diseases such as Mad Cow Disease. After completion of a Phase II Proof of Concept clinical study in October of 2001 for Phenserine, Axonyx's lead product for Alzh...


Alzheimer's Drug Discovery Foundation

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $40 million to fund over 295 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 15 countries.

Alzheimer's Research Foundation

The Fisher Center for Alzheimer's Research Foundation is a leading source of funding for Alzheimer's research. It serves Alzheimer's patients and their families to understand the causes of Alzheimer's, to discover a cure, and to improve the lives of people with the disease. Nobel laureate Dr. Paul Greengard directs the Foundation's team of internationally renowned scientists, who have been at th...

Alzheimer's Research and Prevention Foundation

The Alzheimer's Research and Prevention Foundation (ARPF) is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease. For more information, please visit the Alzheimer's Research and Prevention Foundation at www.alzheimersprevention.o...

EXPERT BIOMED, INC

Expert BioMed offers a service to pharmaceutical companies providing screening of potential drugs on Alzheimer's disease cell and animal models designed and maintained in the company and data interpretation service in addition to the Expert BioMed systems and platform for new drug development. Expert BioMed offers new monoclonal and polyclonal antibodies, recombinant proteins and peptides as bioma...

Alzheimer’s Association, New York City Chapter

Alzheimer’s disease is one of the nation’s largest public health crises. It is the fifth leading cause of death in California and the only leading cause of death that cannot be prevented, cured or even slowed. 630,000 people in California are currently living with Alzheimer’s disease, and more than 1.6 million Californians provide unpaid care for ...

Nova Molecular Incorporated

Nova Molecular Inc. (NMI) is a Montreal based CNS drug discovery company focused on understanding neuronal degeneration, disease progression, repair mechanisms, therapeutic response and development based on our proprietary neuron repair biology platform. NMI’s lead Alzheimer’s compound is also under investigation for a number of other CNS neurodegenerative indications such as Parkinson’s, mu...

Alzheimer's Foundation International

The Alzheimer's Foundation International (AFI) is working toward collaboratively setting a paradigm of quality care for individuals with the disease and their families by raising awareness of Alzheimer's disease and related dementias, providing education, and establishing programs and services that can be replicated in countries around the globe. Currently, AFI's member organizations are the Alzhe...

Alzheon, Inc.

Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Alzheon pursues drug development programs that have previously been tested in extensive efficacy studies in Alzheimer’s disease patients and where new i...

Diagnostic Potentials Ltd

Diagnostic Potentials Ltd is developing a range of diagnostic and monitoring systems for Central Nervous system (CNS) disease states. The first product that has been developed is a system for the early diagnosis of Alzheimer's Disease that will enable clinical consultants to make a positive decision on the care of the patient and on the prescribing of drugs.CNS disorders, such as Alzheimer's, Park...

The Alzheimer's Association

The Alzheimer's Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more informatio...

Curaxis Pharmaceutical Corp

Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that...

Arizona Alzheimer's Consortium

The Arizona Alzheimer's Consortium is a laboratory without walls designed to leverage the strengths of its seven member institutions to promote the scientific understanding of Alzheimer's disease. The Consortium is attacking Alzheimer's disease by combining breakthroughs in genomic medicine and cutting-edge research with data from sophisticated brain imaging programs and advanced clinical trials t...

The Alzheimer’s Association

The Alzheimer’s Association is the world’s leading voluntary health organization in Alzheimer care, support and research. Its mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Learn more ...

Q-RNA, Inc.

Q-RNA, Inc., was founded in 1996 by Abraham Grossman, Ph.D., a molecular biologist with both academic and industry experience. The early efforts of Q-RNA were focused on the development of RNA (ribonucleic acid) ligands and their interaction with proteins. Recent discoveries have put Q-RNA in the forefront of opening the secrets to a vast number of protein misfolding disorders representing major u...

Neuro-Hitech

Neuro-Hitech is focused specifically on the development and commercialization of next-generation therapies against proven targets for neurodegenerative diseases. The company’s signature offering, Huperzine A is being tested for efficacy in the treatment of Alzheimer's disease and the company has plans to study other degenerative disorders such as vascular dementia, mild cognitive impairment and ...

vTv Therapeutics Inc. vTv Therapeutics Inc. vTv Therapeutics Inc.

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflamma...

Avid Radiopharmaceuticals

Founded in 2004, Avid Radiopharmaceuticals, Inc. is a product-focused molecular imaging company that is a pioneer in developing radiopharmaceuticals for imaging Alzheimer's disease pathology. Two of Avid's radiopharmaceuticals are already in clinical trials, and Avid intends to make these products available to pharmaceutical companies that are seeking to develop new drugs for treatment of Alzheime...

Ebixa

Ebixa is an effective, safe and well tolerated therapy, that helps overcome the everyday challenges in Alzheimer’s disease, easing the lives of both patients and their carers. Ebixa is indicated for the treatment of moderate to severe Alzheimer’s disease. Ebixa is a specific, uncompetitive NMDA-receptor antagonist, with a novel mechanism of action that targets the glutamatergic signalling in ...

NeuroNova AB

NeuroNova is leading the development of therapeutic neurogenesis. Our drug development projects are aimed at stimulating processes in the brain that lead to the formation of new neurons. We believe therapeutic neurogenesis can revolutionize the treatment of several currently incurable neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease, as well as certain orphan dru...

Yumanity Therapeutics

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Formed in 2014 by renowned biotech industry leader, Tony Coles, M.D., and protein folding science pioneer, Susan Lindquist, Ph.D., the company is initially focused on discovering disease-modifying therapies for patients with Alzheimer’s di...

Janssen Alzheimer Immunotherapy

Alzheimer's disease (AD), the most common form of dementia, is a fatal, degenerative brain disease that gradually destroys a person's memory and ability to learn, reason, make judgments, communicate and carry out daily activities, such as bathing and eating. As AD progresses, individuals may also experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, delusion...

EPIX Pharmaceuticals

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, ...


More From BioPortfolio on "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks